Jatenergy flags higher than expected revenues for Q3
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Name: Jatenergy Ltd (ASX:JAT)
Market Capitalisation: $38 million
Closing Share Price: 6.3 cents
Jatenergy (ASX:JAT) is a China-Australia cross-border specialist in Fast Moving Consumer Goods (FMCG) exports. It develops in-house brands for Australian products for sale offline and online, with a focus on milk products and baby formula.
Yesterday it released a market update stating that the September quarter revenues are likely to be materially higher than expected (if the market based its assumptions on income generated in recent quarters). This revolves around the finalisation of the August acquisition of 50% of Sydney-based wholesaler, distributor and exporter, Green Forest International.
Green Forest sells to more than 50 shops and pharmacies in Hong Kong, and over 200 gift shops, duty free stores and daigou (‘personal shopper’) warehouses in Australia, as well as Chinese cross-border platform like Taobao and WeChat.
This represents a significant boost to JAT’s distribution capacity and sales. Based on Green Forest’s earnings, JAT’s revenue for the September quarter is expected to be as much as A$8.7 million.
This estimate includes the impact of Green Forest revenue for only half of the September quarter, and it should be noted that 50% of Green Forest’s contributions are associated with minority interests. The December quarter will benefit from a full three month contribution from Green Forest.
The company’s management noted that sales for the June quarter of A$320,000 were relatively low as the company focused its efforts on putting in place the elements necessary to drive sales, particularly of in-house branded products.
NEURIO, a milk powder that’s sold in supermarkets and baby and maternity stores, is a core in-house brand in the small cap’s control that comes from Sunnya, another of JAT’s acquisitions.
However it is an early stage of this company’s development and if considering this stock for your portfolio you should take all public information into account and seek professional financial advice.
JAT to present at Expo
JAT will be showcasing at the inaugural China International Import Expo (CIIE), where Australian businesses are invited to showcase their products and services. Over 500,000 visitors from China and around the world are expected to attend the first expo in November, representing a key opportunity for exposure of JAT’s in-house and client brands.
China is the second largest importer and consumer in the world, and expects to import products and services valued at over US$10 trillion in the next five years. China now takes about two-thirds of Australia’s infant formula exports.
tagsSTOCK MARKET CHINA
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.